Development of an epitope-tagged NAV1.1 transgenic mouse model - SCN1A, encoding the voltage-gated sodium channel (VGSC) NAV1.1, is a major target in neurological disease

Active Grant Awarded

Award ID
R03NS151500
Recipient
Awarding agency
Obligated
$156,000

Award facts

Completion date 10% complete
Place of performance
Ann Arbor, MI 48109, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, awarded Regents of the University of Michigan $156,000 on September 9, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award is a grant under Grant R03NS151500, and it funds development of an epitope-tagged Nav1.1 transgenic mouse model. The project targets SCN1A, which encodes the voltage-gated sodium channel Nav1.1, to enable high-resolution localization of Nav1.1 against the background of other sodium channels in brain neurons. The recipient is the University of Michigan's Office of Research and Sponsored Projects, and the work is performed in Ann Arbor, Michigan 48109. The full $156,000 is obligated, and the period of performance runs from September 9, 2026, through the ultimate completion date of August 31, 2028. The source does not identify any sub-recipients.

Description

Monoallelic SCN1A variants that result in NAV1.1 haploinsufficiency cause the developmental and epileptic encephalopathy (DEE) dravet syndrome (DS) or the less severe genetic epilepsy with febrile seizures plus (gefs+). Gain-of-function SCN1A variants are linked to a more severe, early infantile DEE as well as to familial hemiplegic migraine type 3 (FHM3). Despite the importance of SCN1A in the regulation of neuronal excitability, very little is known about the cell biology of NAV1.1, largely due to the dearth of reliable probes to specifically localize NAV1.1 channels against the background of other vgscs in brain neurons at high resolution. Important questions remain in VGSC cell biology. For example, during brain development, the majority (70%) of newly synthesized VGSC a subunits enter a metabolically stable intracellular pool while the minority (30%) covalently associate with VGSC B2 subunits and insert into the plasma membrane. IT was proposed that intracellular pools of newly synthesized a subunits are localized at axon initial segment (AIS) domains and nodes of ranvier, but this hypothesis was not tested due to lack of appropriate tools. The existence of a large pool of newly synthesized VGSC a subunits in neurons raises important questions about why haploinsufficiency matters in pediatric neurological disease. Our work has demonstrated that treatment of DS mice with the tango antisense oligonucleotide STK-001 corrects NAV1.1 haploinsufficiency and sodium current density as well as restores neuronal excitability. Administration of STK-001 to wildtype mice also increases NAV1.1 expression and sodium current density but does not alter the firing properties of interneurons or result in toxicity. Why not? Where are these newly synthesized vgscs located in neurons? Finally, the specific composition of the "channelome" is critical for the regulation of neuronal excitability, e.g. a particular VGSC a subunit subtype located at the AIS may function differently than the same a subunit located at dendrites due to the differential cohort of modulatory proteins with which the channel associates in these subcellular domains. Future work requires high resolution imaging of NAV1.1 and proteomic identification of NAV1.1 interacting proteins at specific subcellular neuronal domains. A critical unmet need in VGSC biology is the availability of reliable mouse models expressing epitope- tagged VGSC subunits. We have successfully generated transgenic mouse models expressing epitope-tagged NAV1.2 and B1 subunits, respectively, but a tagged NAV1.1 model is not currently available. Thus, this R03 proposal contains a single aim: to generate and validate an epitope-tagged NAV1.1 transgenic mouse line that can be made widely available to the VGSC field through deposition in the jackson laboratories repository. This novel mouse strain will be invaluable to researchers studying DS, gefs+, and FHM3.

Quick answers

Who received award R03NS151500?

R03NS151500 was awarded to Regents Of The University Of Michigan by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.

How much is award R03NS151500 worth?

$156,000 has been obligated on R03NS151500.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award